Treatment Categories
Browse by category to learn how each treatment works and what testing is usually involved.
GLP-1
Peptides
How these treatments are accessed
These treatments aren’t prescribed or dispensed by Testing.com. A prescription comes from a licensed provider, and the medication from a compounding pharmacy. Any baseline lab work or monitoring a provider orders can be processed at CLIA-certified laboratories such as LabCorp and Quest Diagnostics.
| Treatment | Who providers typically consider it for |
|---|---|
| Compounded Tirzepatide | BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. Also considered for type 2 diabetes. Prescriber screens for personal or family history of medullary thyroid carcinoma or MEN2. |
| Compounded Semaglutide | BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. Also considered for type 2 diabetes and cardiovascular risk reduction. |
| NAD+ | Adults exploring energy, cognitive clarity, or recovery support. Prescriber screens for active cancer, pregnancy, and severe organ impairment. |
| Sermorelin | Adults with low or low-normal IGF-1 for age and normal thyroid function. Active malignancy is treated as a contraindication. |
If a provider recommends one of these, baseline lab work is usually ordered first, often at least one blood draw. Fasting requirements depend on which labs the provider orders. Candidacy thresholds for the compounded GLP-1 therapies above reflect the FDA-approved labeling for the branded versions and clinical guidance from the NIDDK.
Frequently Asked Questions
Sources
- National Institutes of Health. “Understanding Laboratory Tests.” MedlinePlus.
- National Institutes of Health. “Nicotinamide Adenine Dinucleotide (NAD+).” National Library of Medicine.
- U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.”
- Cleveland Clinic. “GLP-1 Agonists.”
- National Institute of Diabetes and Digestive and Kidney Diseases. “Prescription Medications to Treat Overweight and Obesity.”